NCT03507452 - First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 13, 2018

Primary Completion Date

September 29, 2021

Study Completion Date

March 29, 2022

Conditions

Advanced Recurrent Malignant Pleural Epithelioid MesotheliomaAdvanced Recurrent Malignant Peritoneal Epithelioid MesotheliomaAdvanced Recurrent Serous Ovarian CancerAdvanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

Interventions

DRUG

BAY2287411

"Dose Escalation part:~A single dose will be administered intravenously on Day 1 of each cycle lasting 6 weeks (42 days)."

DRUG

BAY2287411

"Dose Expansion part:~The selection of the dose level(s) /regimen(s) to be evaluated will be based on the overall benefit / risk and PK profile observed in the dose escalation."

Trial Locations (7)

20892

National Cancer Institute - Maryland, Bethesda

77030

University of Texas MD Anderson Cancer Center, Houston

00290

HUS, Meilahden sairaala, Helsinki

1066 CX

Nederlands Kanker Instituut, Amsterdam

9713 GZ

Universitair Medisch Centrum Groningen, Groningen

221 85

Skånes Universitetssjukhus, Lund

SM2 5PT

Royal Marsden NHS Trust (Surrey), Sutton